secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0001171843-22-006936
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst Q3 ORLADEYO revenue $66M; on track to double 2022 sales; BCX9250 discontinued
--------------------------------------------------------------------------------

- Q3 total revenue $75.8M (+85% YoY); net loss $42.5M ($0.23/share) vs $58.8M ($0.33) in Q3 2021.
- ORLADEYO Q3 net revenue $66.0M; full-year 2022 guidance raised to $255M, more than double 2021.
- BCX9930 partial clinical hold lifted; screening resumed; data from ~15 patients expected mid-2023.
- New oral Factor D inhibitor BCX10013 entered clinic; preliminary data expected Q1 2023.
- Discontinued BCX9250 (FOP) program to redirect ~$100M to complement pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184322006936/0001171843-22-006936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184322006936/f8k_110122.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-006936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer